PD-L1 Expression on Circulating Tumour Cells May Be Predictive of Response to Regorafenib in Patients Diagnosed with Chemorefractory Metastatic Colorectal Cancer

Regorafenib, targeting a broad range of receptor tyrosine kinases (RTKs), is an oral multikinase inhibitor which improves the progression-free survival (PFS) and overall survival (OS) of patients diagnosed with chemorefractory metastatic colorectal cancer (mCRC), making an immunosuppressive tumour m...

Descripción completa

Detalles Bibliográficos
Autores principales: Raimondi, Lucrezia, Raimondi, Filippo Maria, Di Benedetto, Laura, Cimino, Giuseppe, Spinelli, Gian Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7555209/
https://www.ncbi.nlm.nih.gov/pubmed/32962309
http://dx.doi.org/10.3390/ijms21186907

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7555209/
https://www.ncbi.nlm.nih.gov/pubmed/32962309
http://dx.doi.org/10.3390/ijms21186907

Ejemplares similares